|
Streetinvesting.com: Market Review on Cell Genesys, Inc.
(M2 PressWIRE Via Acquire Media NewsEdge)
RDATE:21052008
Streetinvesting.com has now resumed our progressive Cell Genesys, Inc.
(NASDAQ:CEGE) as it opened up $0.12 on below average volume early
trading Wednesday, May 21, 2008. Based on the Company's most recent
news release; we will be progressively reviewing the impact of the
markets and the effects of their developments. We will be providing
updates and analyst opinions as new stories unfold.
Make sure to visit www.streetinvesting.com to keep updated and signup
for free with no credit card for market reports and analytical plays.
Our research resources have been aimed towards the US Large Caps and
the various prospective companies therein Cell Genesys, Inc. was among
those that we have been closely examining due to their recent news and
trading patterns. Sign up at www, streetinvesting.com for more
information on the company mentioned herein.
May 21, 2008, -- Cell Genesys, Inc. reported encouraging interim data
from the expansion cohort of the Phase 1, multicenter clinical trial of
CG0070 in patients with recurrent superficial bladder cancer who had
failed therapy with Bacillus Calmette-Guerin (BCG), the current
standard of care for this patient population. Sixteen patients have
completed dosing of CG0070 administered once weekly or once every four
weeks at the two lowest of three doses being evaluated. Ten of these
sixteen patients showed anti-tumor activity as measured by complete
response at follow-up cystoscopy. These data were presented by James M.
McKiernan, M.D., vice chairman of urology and assistant professor of
urology at Columbia University College of Physicians and Surgeons, at
the annual meeting of the American Urological Association being held in
Orlando, Florida.
Cell Genesys is focused on the development and commercialization of
novel biological therapies for patients with cancer. The company is
currently pursuing two clinical stage product platforms-GVAX cancer
immunotherapies and oncolytic virus therapies. Ongoing clinical trials
include Phase 3 trials of GVAX immunotherapy for prostate cancer, which
is being developed in partnership with Takeda Pharmaceutical Company
Limited, Phase 2 trials of GVAX immunotherapies for pancreatic cancer
and for leukemia, and a Phase 1 trial of CG0070 oncolytic virus therapy
for bladder cancer. Cell Genesys continues to hold an equity interest
in its former subsidiary, Ceregene, Inc., which is developing gene
therapies for neurodegenerative disorders. Cell Genesys is
headquartered in South San Francisco, CA and has its principal
manufacturing operation in Hayward, CA. For additional information,
please visit the company's website at www.cellgenesys.com.
Streetinvesting.com will continue to follow the progress of this
company following their most recent news announcement. Visit
www.streetinvesting.com and signup free for our financial market
services.
At Streetinvesting.com, we bring our knowledge of the marketplace and
investment opportunities directly to our subscribers. As an
aggressive-growth research company, our strength and goal is bringing
distinctive trading opportunities and investment philosophies to
investors seeking a different and unique approach to investment ideas.
That's our goal. That's what we do. We are "The Word on the Street".
Let us become your number one portal for research and information on
the global markets.
To continue with the more in-depth analysis, please visit
www.streetinvesting.com for a complimentary subscription to access this
report and other related articles. Please note that membership does not
require credit card information.
All material herein was prepared by Streetinvesting.com, (Street
Investing) based upon information believed to be reliable. The
information contained herein is not guaranteed by Streetinvesting.com
to be accurate, and should not be considered to be all-inclusive. The
companies that are discussed in this opinion have not approved the
statements made in this opinion. This opinion contains forward-looking
statements that involve risks and uncertainties. This material is for
informational purposes only and should not be construed as an offer or
solicitation of an offer to buy or sell securities. Streetinvesting.com
is not a licensed broker, broker dealer, market maker, investment
banker, investment advisor, analyst or underwriter. Please consult a
broker before purchasing or selling any securities viewed on or
mentioned herein. Streetinvesting.com may receive compensation in cash
or shares from independent third parties or from the companies
mentioned.
Streetinvesting.com's affiliates, officers, directors and employees may
also have bought or may buy the shares discussed in this opinion and
may profit in the event those shares rise in value.
Streetinvesting.com will not advise as to when it decides to sell and
does not and will not offer any opinion as to when others should sell;
each investor must make that decision based on his or her judgment of
the market.
This release contains "forward-looking statements" within the meaning
of Section 27A of the Securities Act of 1933, as amended, and Section
21E the Securities Exchange Act of 1934, as amended and such
forward-looking statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
"Forward-looking statements" describe future expectations, plans,
results, or strategies and are generally preceded by words such as
"may", "future", "plan" or "planned", "will" or "should", "expected,"
"anticipates", "draft", "eventually" or "projected". You are cautioned
that such statements are subject to a multitude of risks and
uncertainties that could cause future circumstances, events, or results
to differ materially from those projected in the forward-looking
statements, including the risks that actual results may differ
materially from those projected in the forward-looking statements as a
result of various factors, and other risks identified in a companies'
annual report on Form 10-K or 10-KSB and other filings made by such
company with the Securities and Exchange Commission.
You should consider these factors in evaluating the forward-looking
statements included herein, and not place undue reliance on such
statements. The forward-looking statements in this release are made as
of the date hereof and Streetinvesting.com undertakes no obligation to
update such statements.
CONTACT: Streetinvesting.com
WWW: http://www.streetinvesting.com
((M2 Communications Ltd disclaims all liability for information
provided within M2 PressWIRE. Data supplied by named party/parties.
Further information on M2 PressWIRE can be obtained at
http://www.presswire.net on the world wide web. Inquiries to
info@m2.com)).
Copyright ? 2008 M2 Communications Ltd.
[ Back To Telecom Expense Management Solutions Global Community's Homepage ]
|
